Results 51 to 60 of about 213,637 (257)

Chemoproteomic Identification of AKT2 as a Paclitaxel‐Binding Protein via C─C Bond‐Linked Probe PTX‐4 in Paclitaxel‐Resistant Breast Cancer

open access: yesAdvanced Science
Breast cancer remains one of the most prevalent malignancies among women, and taxane‐based chemotherapies such as paclitaxel and docetaxel are central to standard treatment regimens.
Kai Wang   +7 more
doaj   +1 more source

Intravitreal Ranibizumab Had Limited Effect on Cystoid Macular Edema Due to Albumin-Bound Paclitaxel: A Case Report and Literature Review

open access: yesFrontiers in Oncology, 2021
Angiographically silent cystoid macular edema (CME) is a rare complication from nab-paclitaxel. Here we report a 45-year-old woman with breast cancer who developed CME after several months of treatment with albumin-bound paclitaxel (nab-paclitaxel).
Suna Ye   +8 more
doaj   +1 more source

Targeting CXCR2 in Nociceptive Sensory Neurons Offers Novel Therapeutic Potentials for Postoperative Pain

open access: yesAdvanced Science, EarlyView.
Tissue incision induces CXCL5 release, which activates neuronal CXCR2 on incision‐innervating sensory neurons. Neuronal CXCR2 couples with TRPA1 to drive mechanical pain and engages p38 MAPK signaling to upregulate TRPV1 and promote heat pain. Targeted Cxcr2 knockdown relieves incisional pain while preserving CXCR2‐dependent neutrophil responses ...
Yushuang Pan   +10 more
wiley   +1 more source

A comparison of paclitaxel and vinblastine induced giant cell formation in murine NK/Ly lymphoma

open access: yesБіологічні студії, 2011
We compared giant cell formation in murine NK/Ly lymphoma under treatment with anticancer drugs – vinblastine or paclitaxel. It was found that vinblastine caused an appearance of bigger cells than paclitaxel did, whereas paclitaxel induced more rapid ...
R. O. Horbay   +2 more
doaj   +1 more source

Recapitulating In Vivo Pharmacokinetics and Size‐Dependent Nanomedicine Delivery in a Microfluidic Platform

open access: yesAdvanced Science, EarlyView.
A microfluidic tumor platform integrates pharmacokinetic flow control, vascular‐like barriers, and 3D tumor spheroids to emulate in vivo drug exposure. The system reproduces dynamic concentration–time profiles and enables size‐dependent nanoparticle transport and efficacy evaluation, providing a predictive framework for assessing nanomedicine ...
Su Jeong Kang   +5 more
wiley   +1 more source

Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Bo Chen   +10 more
wiley   +1 more source

A new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cells. [PDF]

open access: yesPLoS ONE, 2014
Tumor resistance due to multiple mechanisms seriously hinders the efficacy of chemotherapy drugs such as paclitaxel. The most widely studied P-glycoprotein inhibitors still have limited ability to reverse resistance in the clinic.
Mei Mei   +7 more
doaj   +1 more source

Uncoupling Type I Interferon Benefits From Inflammatory Toxicity: Transformer‐Prioritized Precision Agonists for Potent and Safer Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
A Transformer‐based AI framework, DLINP, screens millions of compounds to identify Co68, a cobalt‐pincer organometallic complex that biases TLR4‐MD2 signaling toward antitumor interferon activation while suppressing inflammatory toxicity through an early TLR4‐SYK‐STAT1 axis.
Xuefei Guo   +10 more
wiley   +1 more source

Autophagy Orchestrates Anti‐Tumor Immunity to Enhance Chemosensitivity via the FBXW2/C/EBPβ/TIMP‐2 Axis in Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
Chemotherapy leverages tumor‐cell autophagy to reshape the colorectal cancer immune microenvironment. Autophagy degrades FBXW2 to promote C/EBPβ‐mediated TIMP‐2 transcription and MMP‐9 suppression, driving intra‐tumoral CD8+ T‐cell infiltration. Targeting MMP‐2/9 or restoring TIMP‐2 overcomes chemo‐resistance in autophagy‐deficient tumors. ABSTRACT The
Bing Cheng   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy